I mirror your observations and share the excitement of our CEO for the CNS breakthrough milestones ahead.
Ocular programs and their data breakthrough should see this stock appreciate to 50 cents April to June next year, IMO, with a lot of the buying coming out of the US progressively.
Early funding could propel price earlier, question here is when that will
occur. Management regularly now refers to deepened engagement and
events seem to accelerate.
CNS pipeline initiation in about two months should accelerate large partner commitments.
My impression of events is that those are already watching closely and on some milestones achievement will commit meaningfully.
Exciting times to be invested in this stock
all IMO
Ann: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, page-20
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $17.86K | 137.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1081168 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 505604 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |